WORCESTER, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Nemucore Medical Innovations, Inc., a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women’s cancers, today announced its poster presentation at American Congress of Obstetricians and Gynecologists (ACOG) Annual Clinical Meeting, May 16, 2016, in Washington DC at the Washington Convention Center. Nemucore will present a poster on its targeted therapy NMI-500.
NMI-500 is a folate targeted theranostic containing a taxane therapy designed to overcome multidrug resistance in cancer. Taxane-based chemotherapy is a primary and secondary line of treatment for ovarian cancers, however dose limiting toxicities and multidrug resistance limit their effectiveness.
To improve tumor pharmacodynamics, NMI-500 targets the folate receptor which is expressed on over 80% of ovarian cancers. NMI-500 is also an effective MRI contrast agent; annotated with a gadolinium chelate which allows MRI to be used to identify if NMI-500 is accumulating in tumors. Nemucore has successfully tracked the accumulation of NMI-500 and longitudinally tracked tumor growth using MRI. In preclinical models NMI-500 has shown significant uptake in folate receptor positive tumors with reduced off-target toxicity.
“Multidrug resistant cancer cells require folate to grow, targeting the folate receptor to deliver a highly lethal payload gives us a novel way to kill these aggressive tumors. These results are strong evidence for the importance of targeted therapies to treat drug-resistant cancers," said Timothy Coleman, Ph.D., Nemucore’s Chairman, CEO & President. "Furthermore, this data shows the important role theranostics can play in the creation of personalized medicines. Their unique physical properties can be exploited to overcome difficulties in drug delivery to complex diseases such as ovarian cancer."
About Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women’s cancers. Nemucore's most advanced candidate NMI-900, a potential therapeutic for the treatment of ovarian cancer, is expected to begin a Phase 2b clinical trial in mid-2016. Two additional candidates are anticipated to enter clinical trial development later in 2016, targeting a variety of difficult-to-treat oncology indications, including triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other cancers. For more information, please visit our website at www.Nemucore.com.
Contacts: Tim Coleman (investors) Nemucore Medical Innovations (508) 762-1017 BCC Partners (media) Karen Bergman (650) 323-1717 email@example.com Jen LaVin (207) 360-0473 firstname.lastname@example.org